Pemvidutide vs Semaglutide
Comparing Altimmune's dual GLP-1/glucagon agonist pemvidutide with Novo Nordisk's GLP-1 agonist semaglutide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Pemvidutide
Dossier overview
Semaglutide
Dossier overview
Overview
Pemvidutide (ALT-801) is Altimmune’s investigational dual GLP-1/glucagon receptor agonist being developed for obesity and MASH (metabolic dysfunction-associated steatohepatitis). Like other dual agonists, pemvidutide adds glucagon activity to GLP-1 effects, potentially offering enhanced liver fat reduction and weight loss.
Mechanism Comparison
| Aspect | Pemvidutide | Semaglutide |
|---|---|---|
| Target Receptors | GLP-1 + Glucagon | GLP-1 only |
| Receptor Activity | Dual agonist | Single agonist |
| GLP-1:Glucagon Ratio | Balanced | N/A |
| Unique Feature | Liver fat focus | Proven CV benefit |
Glucagon’s Role in Pemvidutide
Glucagon receptor activation provides:
- Increased hepatic lipid oxidation
- Enhanced energy expenditure
- Greater liver fat reduction
- Potential MASH benefits beyond weight loss
Evidence Comparison
| Aspect | Pemvidutide | Semaglutide |
|---|---|---|
| Development Phase | Phase 2 | FDA Approved |
| Human Trials | MOMENTUM, ongoing | Extensive (STEP, SUSTAIN, SELECT) |
| MASH Data | Phase 2 | Limited |
| CV Outcomes | Not studied | SELECT positive |
Clinical Trial Data
Pemvidutide (MOMENTUM Trial - 48 weeks)
| Dose | Weight Loss |
|---|---|
| 1.8mg weekly | ~10.7% |
| 2.4mg weekly | ~15.6% |
Semaglutide 2.4mg (STEP 1 - 68 weeks)
| Metric | Result |
|---|---|
| Weight Loss | ~14.9% |
| >=10% Weight Loss | 69% |
| >=15% Weight Loss | 51% |
Comparison: Similar weight loss magnitude, though different trial designs.
MASH/Liver Effects
| Outcome | Pemvidutide | Semaglutide |
|---|---|---|
| Liver Fat Reduction | ~70% (MRI-PDFF) | ~50% |
| MASH Focus | Primary development | Not primary |
| Fibrosis Effects | Being studied | Limited data |
Glucagon agonism appears to enhance liver fat reduction beyond GLP-1 alone.
Regulatory Status
| Aspect | Pemvidutide | Semaglutide |
|---|---|---|
| FDA Status | Investigational | Approved |
| Primary Indication | MASH, Obesity | T2D, Obesity, CV risk |
| Phase | Phase 2 | N/A (marketed) |
| Developer | Altimmune | Novo Nordisk |
Administration
| Aspect | Pemvidutide | Semaglutide |
|---|---|---|
| Route | Subcutaneous | SC + Oral |
Side Effect Profile
| Effect | Pemvidutide | Semaglutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| Diarrhea | Common | Common |
| Constipation | Less common | Less common |
Typical incretin-class GI effects for both.
Competitive Landscape
Dual GLP-1/Glucagon Agonists
| Compound | Developer | Status |
|---|---|---|
| Survodutide | Boehringer | Phase 3 |
| Mazdutide | Innovent/Lilly | Phase 3 (China) |
| Pemvidutide | Altimmune | Phase 2 |
Pemvidutide is behind survodutide in development.
Key Differences
| Factor | Pemvidutide | Semaglutide |
|---|---|---|
| Glucagon activity | Yes | No |
| Liver fat reduction | Enhanced | Moderate |
| MASH development | Primary | Not primary |
| Approval status | Investigational | Approved |
| Company size | Small biotech | Large pharma |
Developer Considerations
| Factor | Altimmune (Pemvidutide) | Novo Nordisk (Semaglutide) |
|---|---|---|
| Resources | Limited | Extensive |
| Manufacturing | Scaling challenges | Scaled (with shortages) |
| Commercial capability | Partnership likely | Global infrastructure |
| Development speed | Resource-constrained | Well-funded |
Summary
- Pemvidutide is a dual GLP-1/glucagon agonist with promising liver fat reduction and ~16% weight loss
- Semaglutide is the proven GLP-1 agonist with extensive data, approval, and CV benefit
- Glucagon agonism provides enhanced liver effects relevant for MASH
- Pemvidutide faces competitive pressure from larger players (Boehringer, Lilly)
- MASH indication may be key differentiator for smaller developers
This comparison is for educational purposes only. Pemvidutide is investigational. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.